Search results for: 'structural ad drug'

The discovery of new drug targets for diseases with unmet medical needs has long been hindered by the complexity of processing and interpreting massive volumes of biological data. The increasing volume and veracity of clinical and research data compels the use of enabling tools and technologies, such as cloud computing, AI, machine learning, natura...

For a long time, drug discovery followed the same path and used conventional analysis methods for proposed targets. Today, changes in technology and the ability to study omics are transforming drug development. Personalized therapy is on the rise and promises to be more effective and efficient in addressing challenges. With growing interest in ...

The SynBio field has evolved well over the past two decades, with significant technology disruptions leading to new opportunities and remarkable growth potential. Advances in SynBio technologies have transformed drug discovery and therapeutics development, accelerating the identification of novel drug targets and high-throughput compound screening ...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

17 Sep 2024  |  Global  |  Market Research

ADAS and AD Sensor Suite Strategies, Europe, 2024 2030

OEMs Strategies Will Drive Transformational Growth by Using LiDAR as a Primary Sensor with Cameras and Imaging Radar to Meet the Rise of Eyes-off Driving

Infographics

×

Key Issues Addressed

The global automotive industry is going through a transformation with the convergence of the connected, autonomous, shared, and electric (CASE) trends. Connectivity and autonomous driving (AD) features are leading this transformation. Globally, OEMs are looking to introduce various advanced driver assistance system (ADAS) features ranging from L0 t...

The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...

Server-side ad insertion has normally been about tackling the problems of ad blocking and device fragmentation. But the industry is now seeing platform shifts that change the sweet spot of ad stitching towards live and catch-up TV. Client-side ad SDKs have grown in sophistication, the platforms they run have become more capable and the transition t...

The conventional drug discovery and diagnostics technologies are unable to cope up with the current disease management practices. To this end, researchers have explored possibilities beyond life sciences. Specifically, they have figured out that the use of engineering principles to biological systems can revolutionize the drug discovery and diagnos...

With the healthcare industry moving toward patient convenience and comfort, pharmaceutical and medical device companies are continuously researching for the most effective, side effect free, convenient route of drug delivery. Transdermal drug delivery is a painless method of delivering drug formulation. Transdermal route of drug administration has ...